Background: Gene silencing associated with aberrant methylation of promoter region CpG islands is an acquired epigenetic alteration that serves as an alternative to genetic defects in the inactivation of tumor suppressor genes in human cancers. The demethylating, dose-dependent effect of arsenic trioxide (As2O3) on several tumor-related genes has already been postulated. However, whether such a demethylating effect also applies to the TMS1 gene in chronic myeloid leukemia cell line K562 cells has not been studied so far. The aim of the present study was to detect the methylation status of the TMS1 gene in K562 cells and the demethylation effect of As2O3 on TMS1 as well as TMS1 apoptosis-associated protein Bcl-2/Bax and DNA methyltransferase (DNMT) expression. Methods: TMS1 mRNA expression in K562 cells and normal bone marrow was determined by reverse transcription (RT) polymerase chain reaction (PCR), and the DNA methylation status of the TMS1 promoter in K562 cells treated with different concentrations of As2O3 for 48 h was determined by methylation-specific PCR. RT-PCR and Western blot were used to detect TMS1 and DNMT expression. We also assessed TMS1-associated apoptosis protein Bcl-2/Bax expression by Western blot and apoptosis rates by flow cytometry using annexin V/propidium iodide double staining. Results: In K562 cells, TMS1 was completely methylated and both TMS1 mRNA and protein showed a low expression, but 2 μmol/l As2O3 could significantly restore the expression of the TMS1 gene both at mRNA and protein level (p < 0.01) by fully reversing DNA methylation. As2O3 decreased mRNA and protein expression of DNMT1 (p < 0.05) in a dose-dependent manner. Flow cytometry showed that in the experimental group (2 μmol/l As2O3), cell apoptosis was significantly increased compared with the control group (no As2O3; p < 0.05). In the experimental group, Western blot showed that the expression of the anti-apoptotic protein Bcl-2 was significantly decreased; however, the proapoptotic protein Bax was markedly increased and the Bcl-2/Bax ratio was markedly reduced (p < 0.01). Conclusions: As2O3 could restore the expression of TMS1 by inhibiting DNMT to reverse the hypermethylation and induced apoptosis of K562 cells by downregulation of Bcl-2/Bax expression.

1.
Issa JP: DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007;13:1634-1637.
2.
Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
3.
Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM: TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000;60:6236-6242.
4.
McConnell BB, Vertino PM: Activation of a caspase-9-mediated apoptotic pathway by subcellular redistribution of the novel caspase recruitment domain protein TMS1. Cancer Res 2000;60:6243-6247.
5.
Carvalho JR, Filipe L, Costa VL, Ribeiro FR, Martins AT, Teixeira MR, Jeronimo C, Henrique R: Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis 2010;15:956-965.
6.
Grau E, Martinez F, Orellana C, Canete A, Yanez Y, Oltra S, Noguera R, Hernandez M, Bermudez JD, Castel V: Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients. J Cancer Res Clin Oncol 2010;136:1415-1421.
7.
Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, Picchi MA, Belinsky SA, Herman JG, Taniguchi S, Baylin SB: Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006;66:6210-6218.
8.
Perkins C, Kim CN, Fang G, Bhalla KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2 or Bcl-x(L). Blood 2000;95:1014-1022.
9.
Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997;94:10907-10912.
10.
Sciandrello G, Caradonna F, Mauro M, Barbata G: Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells. Carcinogenesis 2004;25:413-417.
11.
Detich N, Hamm S, Just G, Knox JD, Szyf M: The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem 2003;278:20812-20820.
12.
Ye XS, Liu T, Cui X, Meng WT, Xi YM: Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs (in Chinese). Sichuan Da Xue Xue Bao Yi Xue Ban 2007;38:57-59.
13.
Yang L, Luo JM, Li Y, Liu XJ, Wen SP, Du XY, Yao L, Yang JC, Dong ZR: As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells (in Chinese). Zhonghua Zhong Liu Za Zhi 2009;31:423-427.
14.
Aktas S, Zadeoglulari Z, Ercetin P, Olgun N: The effect of differentiating and apoptotic agents on notch signalling pathway in hepatoblastoma. Hepatogastroenterology 2010;57:891-898.
15.
Liu J, Benbrahim-Tallaa L, Qian X, Yu L, Xie Y, Boos J, Qu W, Waalkes MP: Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells. Toxicol Appl Pharmacol 2006;216:407-415.
16.
Fu HY, Shen JZ, Wu Y, Shen SF, Zhou HR, Fan LP: Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells. Oncol Rep 2010;24:335-343.
17.
Reichard JF, Puga A: Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. Epigenomics 2010;2:87-104.
18.
Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, Hirano S: Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 2006;37:298-311.
19.
Gros C, Fahy J, Halby L, Dufau I, Erdmann A, Gregoire JM, Ausseil F, Vispe S, Arimondo PB: DNA methylation inhibitors in cancer: recent and future approaches. Biochimie 2012;94:2280-2296.
20.
Kang YH, Lee SJ: Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. Oncol Rep 2008;20:637-643.
21.
Masumoto J, Taniguchi S, Ayukawa K, Sarvotham H, Kishino T, Niikawa N, Hidaka E, Katsuyama T, Higuchi T, Sagara J: ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem 1999;274:33835-33838.
22.
Weber CH, Vincenz C: The death domain superfamily: a tale of two interfaces? Trends Biochem Sci 2001;26:475-481.
23.
Ohtsuka T, Ryu H, Minamishima YA, Macip S, Sagara J, Nakayama KI, Aaronson SA, Lee SW: ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell Biol 2004;6:121-128.
24.
McConnell BB, Vertino PM: TMS1/ASC: the cancer connection. Apoptosis 2004;9:5-18.
25.
Virmani A, Rathi A, Sugio K, Sathyanarayana UG, Toyooka S, Kischel FC, Tonk V, Padar A, Takahashi T, Roth JA, Euhus DM, Minna JD, Gazdar AF: Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. Int J Cancer 2003;106:198-204.
26.
Zhang H, He J, Li J, Tian D, Gu L, Zhou M: Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J 2013;27:232-242.
27.
Zhao Y, Gu S, Guo J, Zhang Z, Zhang X, Li X, Chang C: Aberration of p73 promoter methylation in de novo myelodysplastic syndrome. Hematology 2012;17:275-282.
28.
Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y: Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 2005;3:325-334.
29.
Guo J, Zhu CS, Xu WW, Wang Y, Dong L, Bi KH: A preliminary study on the implication of Apaf-1 promoter methylation and the expression of apoptosis inhibitor protein Apollon in adult acute leukemia (in Chinese). Zhonghua Xue Ye Xue Za Zhi 2010;31:736-739.
30.
Gao XN, Yu L: DNA methylation regulates kir3dl1 gene expression in K562 cell line (in Chinese). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:472-475.
31.
Dou LP, Liu JH, Wang C, Zhao Y, Wang QS, Liu JH, Liu CH, Lou FD, Yu L: Study on the involvement of ZO-1 gene in leukemogenesis (in Chinese). Zhonghua Xue Ye Xue Za Zhi 2009;30:473-476.
32.
Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F: Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 2010;10:9-22.
33.
Thomas-Schoemann A, Batteux F, Alexandre J: A new strategy to target regulatory T cells in solid tumors. Oncoimmunology 2013;2:e23338.
34.
Valinluck V, Sowers LC: Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007;67:946-950.
35.
Sumi D, Shinkai Y, Kumagai Y: Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol Appl Pharmacol 2010;244:385-392.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.